Pulmonary embolism (PE) represents the third leading cause of cardiovascular mortality.
The technological landscape for management of acute intermediate-and high-risk PE is …

Intermediate-risk (submassive) pulmonary embolism (PE) describes normotensive patients
with evidence of right ventricular compromise, whereas high-risk (massive) PE comprises …

Objectives: The aim of this study was to evaluate the safety and effectiveness of
percutaneous mechanical thrombectomy using the FlowTriever System (Inari Medical, Irvine …

Background Integrating newly developed tests and treatments for severe pulmonary
embolism (PE) into clinical care requires coordinated multispecialty collaboration. To meet …

Acute pulmonary embolism (PE) leads to an abrupt increase in pulmonary vascular
resistance and right ventricular afterload, and when significant enough, can result in …

Pulmonary embolism (PE) is a major cause of morbidity and mortality in the United States.
Although new therapeutic tools and strategies have recently been developed for the …

Thrombosis of the inferior vena cava (IVC) is an under-recognized entity that is associated
with significant short-and long-term morbidity and mortality. In absence of a congenital …

Pulmonary embolism (PE) is a serious and prevalent cause of vascular disease.
Nevertheless, optimal treatment for many phenotypes of PE remains uncertain. Treating PE …

Purpose To assess device and procedural safety and technical success associated with the
use of the AngioVac System to remove vascular thrombi and cardiac masses. Materials and …

Pulmonary embolism (PE) presents a spectrum of hemodynamic consequences, ranging
from being asymptomatic to a life-threatening medical emergency. Management of …